Ankyra Appoints Sailaja Battula, PhD as Chief Scientific Officer (CSO) [Yahoo! Finance]
Immuneering Corporation - Class A (IMRX)
Company Research
Source: Yahoo! Finance
technology for cancer and other diseases, today announced Sailaja Battula, PhD has been appointed as the new chief scientific officer (CSO) of Ankyra Therapeutics. Dr. Battula brings more than a decade of scientific and leadership experience in immuno-oncology, drug discovery, inflammation, and autoimmunity. She has a proven track record of advancing programs from early discovery through late-stage development, building high-performing teams, and forging strategic collaborations with key opinion leaders, academic institutions, and industry partners. "We are pleased to have Dr. Battula leading our scientific efforts and guiding our emerging pipeline of immune targets," said Howard Kaufman, MD, chief executive officer at Ankyra Therapeutics. "Sailaja's track record of advancing immuno-oncology programs and ability to build high-performing teams bring relevant experience to our growing team." Prior to joining Ankyra, Dr. Battula held leadership roles at several biotechnology companies.
Show less
Read more
Impact Snapshot
Event Time:
IMRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMRX alerts
High impacting Immuneering Corporation - Class A news events
Weekly update
A roundup of the hottest topics
IMRX
News
- Immuneering (IMRX) Valuation After Strong Phase 2a Pancreatic Cancer Data And Planned Phase 3 Transition [Yahoo! Finance]Yahoo! Finance
- Why Immuneering (IMRX) Is Down 29.7% After Positive Phase 2a Pancreatic Cancer Survival Update And What's Next [Yahoo! Finance]Yahoo! Finance
- Immuneering: Strong Buy Despite Decline In Share Price On Atebimetinib Data [Seeking Alpha]Seeking Alpha
- Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnPGlobeNewswire
- Immuneering: Clinical Catalyst In January, Cash Raised For Phase 3 [Seeking Alpha]Seeking Alpha
IMRX
Earnings
- 11/12/25 - Miss
IMRX
Sec Filings
- 2/5/26 - Form 4
- 2/5/26 - Form 4
- 2/5/26 - Form 4
- IMRX's page on the SEC website